202 related articles for article (PubMed ID: 20856130)
21. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
Roche M; Jakobsen MR; Sterjovski J; Ellett A; Posta F; Lee B; Jubb B; Westby M; Lewin SR; Ramsland PA; Churchill MJ; Gorry PR
J Virol; 2011 May; 85(9):4330-42. PubMed ID: 21345957
[TBL] [Abstract][Full Text] [Related]
22. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
Berro R; Klasse PJ; Lascano D; Flegler A; Nagashima KA; Sanders RW; Sakmar TP; Hope TJ; Moore JP
J Virol; 2011 Aug; 85(16):8227-40. PubMed ID: 21680525
[TBL] [Abstract][Full Text] [Related]
23. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
Soulié C; Malet I; Lambert-Niclot S; Tubiana R; Thévenin M; Simon A; Murphy R; Katlama C; Calvez V; Marcelin AG
AIDS; 2008 Oct; 22(16):2212-4. PubMed ID: 18832886
[TBL] [Abstract][Full Text] [Related]
24. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.
Yusa K; Maeda Y; Fujioka A; Monde K; Harada S
J Biol Chem; 2005 Aug; 280(34):30083-90. PubMed ID: 15983047
[TBL] [Abstract][Full Text] [Related]
25. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.
Heredia A; Latinovic O; Gallo RC; Melikyan G; Reitz M; Le N; Redfield RR
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20476-81. PubMed ID: 19075241
[TBL] [Abstract][Full Text] [Related]
26. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
[TBL] [Abstract][Full Text] [Related]
27. A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
Moore JP; Kuritzkes DR
Curr Opin HIV AIDS; 2009 Mar; 4(2):118-24. PubMed ID: 19339950
[TBL] [Abstract][Full Text] [Related]
28. V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance.
Wu E; Du Y; Gao X; Zhang J; Martin J; Mitreva M; Ratner L
J Virol; 2019 May; 93(9):. PubMed ID: 30787151
[TBL] [Abstract][Full Text] [Related]
29. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.
Anastassopoulou CG; Ketas TJ; Sanders RW; Klasse PJ; Moore JP
Virology; 2012 Jul; 428(2):86-97. PubMed ID: 22520838
[TBL] [Abstract][Full Text] [Related]
30. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.
Anastassopoulou CG; Ketas TJ; Depetris RS; Thomas AM; Klasse PJ; Moore JP
Virology; 2011 Apr; 413(1):47-59. PubMed ID: 21356539
[TBL] [Abstract][Full Text] [Related]
31. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
Yuan Y; Maeda Y; Terasawa H; Monde K; Harada S; Yusa K
Virology; 2011 May; 413(2):293-9. PubMed ID: 21440278
[TBL] [Abstract][Full Text] [Related]
32. Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
Yuan Y; Yokoyama M; Maeda Y; Terasawa H; Harada S; Sato H; Yusa K
PLoS One; 2013; 8(6):e65115. PubMed ID: 23840315
[TBL] [Abstract][Full Text] [Related]
33. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
McNicholas P; Vilchez RA; Greaves W; Kumar S; Onyebuchi C; Black T; Strizki JM
J Clin Virol; 2012 Oct; 55(2):134-9. PubMed ID: 22824230
[TBL] [Abstract][Full Text] [Related]
34. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
35. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Recordon-Pinson P; Raymond S; Bellecave P; Marcelin AG; Soulie C; Descamps D; Calvez V; Harrigan PR; Fleury H; Izopet J; Masquelier B;
Antimicrob Agents Chemother; 2013 Feb; 57(2):930-5. PubMed ID: 23208718
[TBL] [Abstract][Full Text] [Related]
37. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
[TBL] [Abstract][Full Text] [Related]
38. [Mechanisms of resistance and failure of treatment with maraviroc].
Delgado R
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():28-33. PubMed ID: 19133219
[TBL] [Abstract][Full Text] [Related]
39. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
Kuhmann SE; Pugach P; Kunstman KJ; Taylor J; Stanfield RL; Snyder A; Strizki JM; Riley J; Baroudy BM; Wilson IA; Korber BT; Wolinsky SM; Moore JP
J Virol; 2004 Mar; 78(6):2790-807. PubMed ID: 14990699
[TBL] [Abstract][Full Text] [Related]
40. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Swenson LC; Chui CK; Brumme CJ; Chan D; Woods CK; Mo T; Dong W; Chapman D; Lewis M; Demarest JF; James I; Portsmouth S; Goodrich J; Heera J; Valdez H; Harrigan PR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6122-30. PubMed ID: 24080655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
